Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives

This is the authors' abstract. We don't add key points for this paper.

The landscape of cancer treatment is rapidly evolving with the emergence of promising novel therapies, offering new hope for patients with challenging malignancies. This review explores key advancements, including next-generation immunotherapies targeting novel biomarkers, innovative cell therapies, personalized neoantigen-based treatments, gene therapies, and advanced drug delivery systems. Immunotherapies are expanding beyond traditional checkpoints, with new targets such as ITPRIPL1 and LILRBs showing promising potential to enhance antitumor immunity. Cell therapies beyond autologous chimeric antigen receptor-T (CAR-T), such as in vivo CAR-T, are advancing with improved manufacturing processes. Gene therapies, such as miRNA-targeting approaches and plant immune protein RDR1, offer new strategies for restoring gene expression. Additionally, mRNA-based therapies are gaining traction for their precision in delivering therapeutic agents, while novel drug delivery systems are improving treatment efficacy and specificity. These therapies, while promising, face challenges such as the early-stage nature of most trials, which limits conclusions about long-term efficacy and safety, the potential insufficiency of monotherapies targeting these pathways, and issues related to stability and cell permeability. Future research will focus on optimizing these therapies to maximize their clinical impact and explore synergistic combinations for enhanced efficacy.